Prelude Therapeutics price target raised to $6 from $3 at Citizens
Citizens raised the firm’s price target on Prelude Therapeutics (PRLD) to $6 from $3 and keeps an Outperform rating on the shares following the Q4 report. The preclinical JAK2V617F data support potential best-in-class selectivity and disease modifying potential, the analyst tells investors in a research note. Citizens believes Prelude shares “represent a unique investment opportunity with meaningful upside.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on PRLD:
Disclaimer & DisclosureReport an Issue
- Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
- Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
- Prelude Therapeutics sees cash runway into 2Q27
- Prelude Therapeutics Wins FDA IND Clearance for PRT12396
- Prelude receives FDA clearance for investigational IND for PRT12396
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LAZARD, INC. <LAZ.N>: KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
LAZARD, INC. : KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
What Stocks Will Shine When the AI Bubble Bursts? John Rogers Says Look to Smucker's
GFL ENVIRONMENTAL INC. <GFL.TO>: CIBC CUTS TARGET PRICE TO C$77 FROM C$82
GFL ENVIRONMENTAL INC. : CIBC CUTS TARGET PRICE TO C$77 FROM C$82
Gold edges higher after hitting a two-month low
Crypto prices
More
